eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2022
vol. 26
 
Share:
Share:
abstract:
Original paper

Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer

Shinichiro Okauchi
1
,
Kunihiko Miyazaki
2
,
Hiroaki Satoh
1

  1. Mito Medical Center, University of Tsukuba, Japan
  2. Ryugasaki Saiseikai Hospital, Japan
Contemp Oncol (Pozn) 2022; 26 (2): 123–127
Online publish date: 2022/06/30
View full text Get citation
 
PlumX metrics:
Introduction
For epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC), no studies have treated the site of recurrence after first-line tyrosine kinase inhibitor (TKI) treatment as a “metastasis pattern”. This study aims to assess whether these patients have a specific “metastasis pattern” at the site of recurrence after the treatment.

Material and methods
Data were collected from all consecutive EGFR mutated NSCLC patients between 2009 and 2021. Metastatic patterns were analyzed using cluster analysis in patients with EGFR mutated NSCLC.

Results
During the study period, 83 EGFR mutated NSCLC patients were treated with EGFR-TKI. Patients who had no metastases at the time of diagnosis were divided into two groups according to the presence or absence of recurrence of metastases after TKI administration. Patients with metastases at diagnosis were divided into 4 groups by cluster analysis. A statistically significant difference in metastasis frequency was confirmed among these 6 groups (2 test, p = 0.0001). Furthermore, when the frequency of metastasis recurrence after TKI administration in these 6 groups was examined, a statistically significant difference was confirmed (2 test, p = 0.0001).

Conclusions
Even in EGFR mutation-positive patients, the knowledge of the recurrent patterns might be useful for clinical practice in the foreseeable future, as it enables more efficient detection of metastatic disease through imaging, and more effective treatment at predicted metastatic sites.

keywords:

cluster analysis, deterioration, metastasis, recurrence, first-line EGFR-TKI, EGFR mutated NSCLC

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.